Grippferon [Interferon alfa 2b]

Gripferon is a 10 ml nasal spray bottle in the form of a clear, colorless or light yellow solution. Its active ingredient is human recombinant interferon alfa 2b, 10,000 IU/1 ml. Inactive ingredients include disodium edetate dihydrate - 0.5 mg, sodium chloride - 4.1 mg, disodium phosphate dodecahydrate - 11.94 mg, monopotassium phosphate - 4.54 mg, povidone 8,000 - 10 mg, macrogol 4,000 - 100 mg and purified water - up to 1 ml.

Application and dosage

At the first signs of a disease Grippferon is prescribed for 5 days. Dosage for adults and children from 15 years of age is 3 doses in each nasal passage 5–6 times a day (maximum single dose is 2,000 IU, maximum daily dose is 15,000–18,000 IU).


  • individual intolerance to interferon or the components of the drug;
  • severe allergies.
  • Grippferon is approved for use during pregnancy and lactation.

    Side effects

    Side effects are not registered.

    Drug interaction

    Co-administration of Grippferon with other nasal decongestants is not recommended as it can cause dry nose. It can be used in conjunction with vaccination.


    Cases of overdose are not registered.

    Storage conditions

    Keep out of the reach of children. Store at a temperature 2-8°C(35-46 °F). Shelf life is 2 years. Open bottle to be stored for no more than 30 days.

    Country of manufacture: Russia

    Grippferon is a drug based on a highly active recombinant (artificially produced) interferon alfa 2b; it has immunomodulating, anti-inflammatory and antiviral properties.

    The effects of interferon alfa 2b:

  • Antiviral effect lies in activation of protective mechanisms of virus-free cells that prevent the virus entry and assembly of virions.
  • Immunomodulating effect. Interferon alfa 2b activates macrophages, T cells and NK cells (Natural-killer cells), increases phagocytosis and antigen processing and presentation mediated by major histocompatibility complex (MHC) and stimulates proliferation and differentiation of bone marrow cells, therefore enhancing the mechanism of antiviral protection.
  • Anti-inflammatory effect, which is due to the immune system reactions boosted by interferon alfa 2b.
  • In contrast to other drugs containing interferon, Grippferon prevents the viruses’ reproduction in the nasal mucosa – exactly where the viruses enter the body. It can help with viral infections.


    Prevention and treatment of influenza and acute respiratory viral infection (ARVI) in children and adults.

  • after contact with a patient and/or cold exposure use 1 dose in accordance with the age prescriptions above 2 times a day;
  • in order to prevent seasonal sickness and stimulate the immune system use 1 dose in accordance with the age prescriptions above in the morning every 1 or 2 days.
  • If necessary, prophylactic administration can be repeated.

    The drug is also prescribed to children from 1 year of age.

    1. R Spiegel et al (1986) Intron A (interferon alfa-2b): clinical overview and future directions
    2. Sokal et al (1993) Interferon alfa-2b therapy in children with chronic hepatitis B
    3. Campistol et al (1999) Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment
    4. Dubois et al (1999) Toxicity profile of interferon alfa-2b in children: A prospective evaluation
    5. Dithmar et al (2000) Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study
    6. Glue et al (2000) A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group
    7. Wong et al (2000) Cost effectiveness of ribavirin/interferon alfa-2b after interferonrelapse in chronic hepatitis C
    8. Cameron et al (2001) Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study
    9. Dieperink et al (2003) A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C
    10. Dang et al (2004) Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease
    11. Keilholz et al (2005) Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
    12. Wiegand et al (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study
    13. Solti et al (2007) A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment
    14. Rusciani et al (2007) Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up
    15. McHutchison et al (2008) Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C
    16. A Tarhini, J Kirkwood (2009) Clinical and immunologic basis of interferon therapy in melanoma
    17. Mori et al (2009) Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy
    18. Bottomley et al (2009) Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
    19. Papadopoulos et al (2009) Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study
    20. Al-Zahrani et al (2014) Successful interferon-alpha 2b therapy for unremitting warts in a patient with DOCK8 deficiency
    21. Meshcheriakova et al (2014) The influence of gel-like recombinant interferon α-2b on the clinical course of acute respiratory infection and the state of mucosal immunity in the pregnant women

    Type: Unknown Type